Leflunomida Stada

Leflunomide, the active ingredient in Leflunomida Stada, is a disease-modifying antirheumatic drug (DMARD) presented as an oral formulation for systemic use. It is employed to manage rheumatoid arthritis and psoriatic arthritis in adult patients, reducing disease activity and slowing joint damage.

GNH USA supplies Leflunomida Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its global network ensures timely delivery and compliance with local regulatory requirements.

Leflunomide, a disease-modifying antirheumatic drug (DMARD), is used to treat inflammatory joint disorders.

- Rheumatoid arthritis: reduces joint inflammation, pain, and structural damage, improving functional ability in adult patients. - Psoriatic arthritis: alleviates joint swelling and skin lesions, slowing disease progression and enhancing quality of life. - Moderate to severe rheumatoid arthritis in patients with inadequate response to conventional DMARDs: offers an alternative therapeutic option to control disease activity. - Adult patients with active rheumatoid arthritis requiring long‑term disease control: helps maintain remission and prevent radiographic progression.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Diarrhoea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Alopecia: reversible hair thinning. - Elevated liver enzymes: mild transaminase increase. - Hypertension: modest rise in blood pressure. - Rash: non‑specific skin eruption.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury or failure. - Severe infections: opportunistic or bacterial infections requiring medical attention. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Bone marrow suppression: neutropenia or anemia. - Stevens‑Johnson syndrome: severe skin and mucosal reaction. - Teratogenicity: potential fetal harm if exposure occurs during pregnancy.

Patients should be monitored and counseled before and during therapy.

- Liver monitoring: perform baseline and periodic liver function tests. - Blood pressure: check regularly and manage hypertension if present. - Pregnancy: avoid use during pregnancy and discontinue if pregnancy is confirmed. - Infection risk: assess for active infections before initiating treatment. - Hematology: monitor complete blood count for signs of bone‑marrow suppression. - Store at below 25°C: keep in the original pack, protect from moisture.

Leflunomide may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Methotrexate: increased risk of hepatotoxicity and bone‑marrow suppression. - Warfarin: enhanced anticoagulant effect, raising bleeding risk. - Live vaccines: heightened chance of infection; avoid concurrent administration.

Moderate Interactions (Monitor Closely): - Statins: possible increased risk of myopathy. - Azathioprine: additive bone‑marrow suppression. - Oral contraceptives: reduced efficacy, consider alternative contraception.